REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.49 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $393,000 | -17.4% | 15,641 | -0.1% | 0.00% | 0.0% |
| Q2 2022 | $476,000 | -47.7% | 15,649 | -43.7% | 0.00% | 0.0% |
| Q1 2022 | $911,000 | +120.6% | 27,801 | +77.7% | 0.00% | 0.0% |
| Q4 2021 | $413,000 | -73.8% | 15,649 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $1,574,000 | -28.9% | 15,649 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $2,215,000 | +39.5% | 15,649 | -1.7% | 0.00% | +50.0% |
| Q1 2021 | $1,588,000 | -58.9% | 15,926 | -49.1% | 0.00% | -33.3% |
| Q4 2020 | $3,868,000 | +153.5% | 31,282 | +99.8% | 0.00% | 0.0% |
| Q3 2020 | $1,526,000 | -37.5% | 15,659 | 0.0% | 0.00% | -40.0% |
| Q2 2020 | $2,443,000 | +8.2% | 15,659 | +0.1% | 0.01% | 0.0% |
| Q1 2020 | $2,258,000 | -29.4% | 15,641 | 0.0% | 0.01% | -16.7% |
| Q4 2019 | $3,197,000 | +263.7% | 15,641 | +42.9% | 0.01% | +200.0% |
| Q3 2019 | $879,000 | -14.9% | 10,947 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,033,000 | – | 10,947 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $288,821,000 | 55.24% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 100,000 | $9,970,000 | 15.20% |
| Tolleson Wealth Management, Inc. | 108,000 | $10,768,000 | 3.25% |
| MADDEN SECURITIES Corp | 34,787 | $3,468,000 | 2.03% |
| Biondo Investment Advisors, LLC | 101,204 | $10,090,000 | 2.01% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,027,000 | 1.91% |
| Duquesne Family Office | 749,897 | $74,765,000 | 1.65% |
| Sofinnova Investments, Inc. | 238,520 | $23,780,000 | 1.43% |
| Camber Capital Management LP | 400,000 | $39,880,000 | 1.37% |
| Integral Health Asset Management, LLC | 44,000 | $4,387,000 | 1.25% |